<DOC>
	<DOCNO>NCT02425306</DOCNO>
	<brief_summary>This study evaluate whether safe administer peptide vaccine combination different adjuvant . Adjuvants substance may boost immune response vaccine . In study , adjuvant Montanide ISA-51 , polyICLC cyclophosphamide . This study also evaluate effect combination peptide vaccine adjuvant immune system . The investigator monitor effect perform test laboratory participant ' blood , lymph node , tissue site vaccination .</brief_summary>
	<brief_title>Safety Study Helper Peptide Vaccine Plus Adjuvant Combinations Treatment Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>Part 1 : Participants stage IIB , IIC , III , IV melanoma original diagnosis restaging recurrence . Patients highrisk stage IIA melanoma ( DecisionDx Melanoma test , Castle Biosciences , Inc , ; Friendswood , TX ) also may eligible . These participant may cutaneous , uveal , mucosal primary melanoma , unknown primary melanoma . Diagnosis melanoma must confirm cytological histological examination . Staging cutaneous melanoma base version 7 AJCC stag system . Part 2 : Patients diagnosis stage IIIBIV melanoma one tumor deposit accessible biopsy and/or excision . These participant may cutaneous , uveal , mucosal primary melanoma , unknown primary melanoma . Diagnosis melanoma must confirm cytological histological examination . Staging cutaneous melanoma base version 7 AJCC stag system . Patients must adequate cutaneous , subcutaneous , soft tissue , nodal metastasis melanoma readily accessible biopsy Participants require radiological study rule radiologically evident disease . Required study include : Chest CT scan , Abdominal pelvic CT scan , Head CT scan MRI PET/CT fusion scan may replace scan chest , abdomen , pelvis . Participants brain metastasis eligible follow true : Each brain metastasis must completely remove surgery unresected brain metastasis must treat stereotactic radiosurgery . There evident growth brain metastasis since recent treatment . No brain metastasis &gt; 2 cm diameter time registration . The recent surgical resection gammaknife therapy malignant melanoma must complete ≥ 1 week Part 1 , ≤ 6 month prior registration . All participant must : ECOG performance status 0 1 ( Appendix 3 ) Ability willingness give inform consent Laboratory parameter follow : ANC &gt; 1000/mm3 Platelets &gt; 100,000/mm3 Hgb &gt; 9 g/dL HgbA1c ≤ 7.5 % Hepatic : AST ALT ≤ 2.5 x upper limit normal ( ULN ) Bilirubin ≤ 2.5 x ULN ( except patient Gilbert 's disease , bilirubin 4x ULN allow ) Alkaline phosphatase ≤ 2.5 x ULN Renal Creatinine ≤ 1.5 x ULN Serology ( within 6 month study entry ) HIV negative Hepatitis C negative ( evidence active virus ) Blood collect HLA type ( Class I Class II ) , analyzed part immunologic endpoint , HLA type inclusion/exclusion criterion . Age 18 year old registration . Part 1 : Participants must least two intact ( undissected ) axillary and/or inguinal lymph node basin . Part 2 : Participants must least one intact ( undissected ) axillary and/or inguinal lymph node basin . Participants receive follow medication treatment time within 4 week registration : Chemotherapy Interferon ( e.g . IntronA® ) Radiation therapy ( Stereotactic radiotherapy , gamma knife , use ≥ 1 week ≤ 6 month prior registration ) Allergy desensitization injection High dos systemic corticosteroid , follow qualification exception : In patient adrenal pituitary insufficiency replacement steroid dose allow ; however , daily dose 10 mg prednisone ( equivalent ) per day administer parenterally orally allow patient normal adrenal pituitary function . Inhaled steroid ( e.g . : Advair® , Flovent® , Azmacort® ) permit low dos ( less 500 mcg fluticasone per day , equivalent ) ( 76,77 ) . Topical , nasal , intraarticular corticosteroid acceptable . Growth factor ( e.g . Procrit® , Aranesp® , Neulasta® ) Interleukins ( e.g . Proleukin® ) Any investigational medication Targeted therapy specific mutate BRAF MEK Participants currently receive nitrosoureas receive therapy within precede 6 week Participants currently receive checkpoint molecule blockade therapy , receive therapy within precede 12 week . Participants know suspected allergy component vaccine . Participants may vaccinate previously synthetic peptide include protocol . Participants receive vaccination contain agent synthetic peptide include protocol recur administration vaccine eligible enroll 12 week follow last vaccination . Pregnancy . Female participant childbearing potential must negative pregnancy test ( urinary serum betaHCG ) obtain within 2 week prior registration . Males female must agree , consent form , use effective birth control method course vaccination . Female participant must breastfeed Participants medical contraindication potential problem complying requirement protocol opinion investigator . Participants classify accord New York Heart Association classification Class III IV heart disease ( Appendix 4 ) . Participants uncontrolled diabetes , define HgbA1c ≥ 7.5 % . Participants must prior autoimmune disorder require cytotoxic immunosuppressive therapy , autoimmune disorder visceral involvement . Participants active autoimmune disorder require therapy also exclude . The following exclusionary : The presence laboratory evidence autoimmune disease ( e.g . positive ANA titer ) without symptom Clinical evidence vitiligo Other form depigmenting illness Mild arthritis require NSAID medication Participants another cancer diagnosis , except follow diagnosis allow : squamous cell cancer skin without know metastasis basal cell cancer skin without know metastasis carcinoma situ breast ( DCIS LCIS ) carcinoma situ cervix cancer without distant metastasis treat successfully , without evidence recurrence metastasis 5 year Participants know addiction alcohol drug actively take agent , participant recent ( within 1 year ) ongoing illicit IV drug use . Body weight &lt; 110 pound ( without clothes ) registration , due amount frequency blood drawn .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>peptide</keyword>
	<keyword>vaccine</keyword>
	<keyword>adjuvant</keyword>
	<keyword>polyICLC</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>Montanide ISA-51</keyword>
</DOC>